Researchers across the UK are investigating whether a combination of two drugs, an acetylcholinesterase inhibitor, for example, donepezil (also called Aricept) and memantine, can be used to treat dementia with Lewy Bodies and Parkinson’s dementia.

• There is evidence about memantine for people living with Alzheimer’s, but answers are needed about whether memantine is an effective treatment in Lewy body dementia.

Who can take part?

• 300 people with DLB (dementia with Lewy bodies) or Parkinson’s dementia
• who are aged over 55
• who have been taking an acetylcholinesterase inhibitor medication such as donepezil or rivastigmine for at least 12 weeks

All participants will be asked to take part with a trial partner, such as a family member or carer.

What is involved?

• You will be asked to take either the study drugs or a placebo drug for 52 weeks
• You will take part in three in-person visits at your local research hospital or at home
  • These visits will involve blood tests, surveys and physical assessments
  • Each visit will last around two hours
  • Travel expenses will be reimbursed

• You will also take part in five telephone consultations
• • These calls should last between 10 and 20 minutes

Interested in taking part?

You can self-refer or be referred by a family member or carer or clinician. A researcher will then contact you to see if you are eligible to join the study.

There are nearly 30 study sites spread throughout the UK. To find out more about taking part or locate a team near you, contact the COBALT trial team.